- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.04. | Chugai Q1 2026: Starkes Auslandsgeschäft und Pipeline-Fortschritte treiben Wachstum an | 11 | Investing.com Deutsch | ||
| 24.04. | Chugai Q1 2026 slides: overseas sales surge, pipeline advances | 19 | Investing.com | ||
| 24.04. | Chugai Pharmaceutical meldet starkes Umsatzwachstum für Q1 2026, Aktie gibt dennoch nach | 13 | Investing.com Deutsch | ||
| 24.04. | Chugai Pharmaceutical reports Q1 results | 2 | Seeking Alpha | ||
| 24.04. | Chugai Pharma Q1 Results Climb, Backs FY26 Outlook | 651 | AFX News | TOKYO (dpa-AFX) - Japan's Chugai Pharmaceutical Co., Ltd. (CHGCF.PK, 4519.T) reported Friday higher profit and revenues for its first quarter, and maintained fiscal 2026 outlookIn the first... ► Artikel lesen | |
| 20.04. | Chugai Pharmaceutical: Starke Verkaufsstarts bei Adipositas-Medikament treiben Aktie an | 2 | Investing.com Deutsch | ||
| 13.03. | Excillum and Chugai Technos announce partnership to introduce advanced battery inspection systems in Japan | 5 | Cision News | ||
| CHUGAI PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 30.01. | Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech | 6 | FierceBiotech | ||
| 29.01. | Chugai Pharmaceutical FY2025 slides: Record profits amid pipeline evolution | 3 | Investing.com | ||
| 29.01. | Chugai: Rekordgewinn im Geschäftsjahr 2025 - Pipeline-Anpassung verunsichert Anleger | 10 | Investing.com Deutsch | ||
| 29.01. | Chugai Pharmaceutical: Rekordgewinne im Geschäftsjahr 2025, doch Aktie gibt nach | 3 | Investing.com Deutsch | ||
| 29.01. | Chugai Pharmaceutical reports FY results | 2 | Seeking Alpha | ||
| 29.01. | Chugai Pharma FY25 Results Climb, Sees Growth In FY26 Core Profit, Revenues | 586 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) reported Thursday higher profit and revenues in fiscal 2025. The company further announced year-end dividends, and lower fiscal 2026... ► Artikel lesen | |
| 22.12.25 | Chugai Secures Regulatory Nod For Tecentriq In Thymic Carcinoma | 645 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) on Monday announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Tecentriq Intravenous Infusion for an... ► Artikel lesen | |
| 25.11.25 | Chugai Reports Positive Data From TEIEN Study Of Port Delivery System With Ranibizumab In NAMD & DME | 610 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) on Tuesday reported positive results from its phase I/II TEIEN study evaluating the Port Delivery System with Ranibizumab (PDS) in... ► Artikel lesen | |
| 25.11.25 | Chugai Pharmaceutical Teams With Biomy For Development Of AI-based Cancer Pathology Program | 677 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCY.PK), Tuesday announced a Memorandum of Understanding with Biomy, Inc., a provider of innovative services for pharmaceutical companies... ► Artikel lesen | |
| 24.10.25 | Chugai Pharmaceutical 9-month Net Income Rises | 627 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Chugai Pharmaceutical Co. reported, on a IFRS basis, nine month net income of 305.6 billion yen, up 3.3% from a year ago. Revenue was 911.6 billion yen,... ► Artikel lesen | |
| 17.10.25 | Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 ... | 770 | GlobeNewswire (Europe) | Rani will receive $10 million upfront payment and is eligible to receive up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones and single digit... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TRULIEVE CANNABIS | 8,050 | -3,94 % | Trulieve's NYSE Listing Is Historic. But Is the Stock Still Worth Buying? | ||
| WEST PHARMACEUTICAL SERVICES | 287,80 | +0,91 % | Is West Pharmaceutical Stock Outperforming the S&P 500? | ||
| SHIONOGI | 15,040 | +0,84 % | UBS stuft Shionogi-Aktie hoch: Günstige Bewertung und Pipeline als Kaufargumente | ||
| KALA BIO | 3,340 | -7,48 % | XFRA 27F: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILKALA BIO INC. O.N.... ► Artikel lesen | |
| CHARLOTTES WEB | 0,224 | -5,88 % | Charlotte's Web Holdings, Inc.: Charlotte's Web Announces Board Transition as Co-Founder Jared Stanley Deepens Focus on DeFloria | Louisville, Colorado--(Newsfile Corp. - June 5, 2026) - Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) ("Charlotte's Web" or the "Company"), a botanical wellness innovation company and... ► Artikel lesen | |
| BEXIMCO PHARMACEUTICALS | 0,380 | -14,80 % | Beximco Pharma. - First patients access affordable CF medicine | ||
| MIRUM PHARMACEUTICALS | 94,12 | +1,03 % | Mirum Pharmaceuticals, Inc. - 8-K, Current Report | ||
| LUYE PHARMA | 0,212 | -2,75 % | LUYE PHARMA (02186): VOLUNTARY ANNOUNCEMENT THE PHASE 2 CLINICAL TRIAL IN CHINA OF THE GROUP'S NEW DRUG LY03015 (A VMAT2 INHIBITOR/SIGMA-1R AGONIST) ... | ||
| PERCHERON THERAPEUTICS | 0,001 | 0,00 % | Percheron Therapeutics completes cancer treatment drug substance manufacture milestone | ||
| AYURCANN | 0,001 | 0,00 % | Red White & Bloom Brands Inc.: Red White & Bloom Brands' Subsidiary, Emblem Cannabis Corporation, Completes Acquisition of Ayurcann's Health Canada-Licensed Manufacturing Operations, Leading Vape & Pre-Roll Brands | TORONTO, June 08, 2026 (GLOBE NEWSWIRE) -- Red White & Bloom Brands Inc. (CSE: RWB) ("RWB" or the "Company") is pleased to announce that, in connection with the insolvency proceedings of Ayurcann Inc.... ► Artikel lesen | |
| KALBE FARMA | 0,029 | -3,39 % | Dividendenbekanntmachungen (04.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A-LIVING SMART CITY SERVICES CO LTD CNE100002RY5 0,0688 HKD 0,0075 EUR ADESSO SE DE000A0Z23Q5 - 0,78 EUR AGEAS SA/NV ADR US00844W2089 2... ► Artikel lesen | |
| AVANT BRANDS | 0,332 | -0,60 % | Avant Brands Inc.: Avant Brands Announces Voting Results from Its 2026 Annual General and Special Meeting of Shareholders | KELOWNA, BC / ACCESS Newswire / May 4, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU) ("Avant" or the "Company"), is pleased to announce the voting results from its annual general and special... ► Artikel lesen | |
| EVEREST MEDICINES | 2,780 | -4,79 % | Everest Medicines Limited: Everest Medicines Enters into Exclusive Licensing Agreement with Dimerix for DMX-200 in Greater China, South Korea and Southeast Asia | HONG KONG, June 16, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK)announced that it has entered into an exclusive licensing agreement with Australia Dimerix Limited ('Dimerix'), for the development... ► Artikel lesen | |
| KOBAYASHI PHARMACEUTICAL | 27,800 | +0,72 % | Kobayashi Pharmaceutical Co., Ltd. Profit Declines In Full Year | TOKYO (dpa-AFX) - Kobayashi Pharmaceutical Co., Ltd. (KBYPF) announced earnings for full year that Dropped, from last yearThe company's earnings came in at JPY3.656 billion, or JPY49.19 per... ► Artikel lesen | |
| BAYER | 38,010 | +2,31 % | EQS-PVR: Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer Aktiengesellschaft: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
15.06.2026... ► Artikel lesen |
CHUGAI PHARMACEUTICAL CO LTD ADR gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 19,400 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHUGAI PHARMACEUTICAL CO LTD ADR finden Sie auf Wallstreet Online.